source
- Blackstone pledges up to $1.5 billion to fund Pfizer's obesity drug berobenatide developmentBlackstone Life Sciences has agreed to provide up to $1.5 billion to support the research and development of Pfizer's obesity candidate, berobenatide, which originated from the former Metsera progr…
- BMS consolidates R&D under chief medical officer Cristian Massacesi as chief research officer Robert Plenge exitsBristol Myers Squibb announced that starting Jan. 1, its chief medical officer and head of development, Cristian Massacesi, will lead a newly combined research and development unit, merging previou…